The Peptide Desk The Peptide Desk
KPV Oral, product photo
Immune Oral

KPV Oral

KPV Oral - tripeptide Lys-Pro-Val with anti-inflammatory action. Research application in inflammatory bowel diseases.

  • Ships from Germany

Order

Unit price -
  • DHL with tracking
  • Discreet packaging
At a glance

KPV Oral by the numbers

The key figures from our lexicon.

Full lexicon entry
Class
Anti-inflammatory tripeptide

oral

Use
Oral

tablet, 500mcg

Sizes
250 mcg

1 size in the shop

What studies show

  1. 1

    PepT1-mediated uptake of the tripeptide KPV reduces intestinal inflammation (preclinical) (opens in a new tab)Dalmasso et al., Gastroenterology, 2008

The source in the lexicon

For research and educational purposes only. Values from the TPD lexicon, sources linked there.

There is no lab analysis for KPV Oral yet. Vote for itAll lab analyses

Knowledge

Everything about KPV Oral

Description

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) and shares the anti-inflammatory action of the parent compound without the pigmentary effects. The substance was developed at the National Institutes of Health and shows strong anti-inflammatory action especially in the gastrointestinal tract in preclinical studies.

Per study reports KPV binds to melanocortin receptors MC1R and MC5R with anti-inflammatory signal cascade. Cellular effects include reduction of NF-kB activation, inhibition of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1) and modulation of Th17/Treg balance.

In studies on colitis models (DSS colitis, TNBS colitis) KPV showed significant reduction of intestinal wall inflammation and improvement of histological markers. Oral application is particularly valuable here due to local action at target tissue.

Pharmacokinetically orally bioavailable with moderate systemic bioavailability, good action locally in the gastrointestinal tract. Half-life short, daily dosing common.

You can order KPV Oral as oral tablets in one bottle with 500mcg per tablet.

This information is for research and educational purposes only. No medical recommendations.

Risks & Safety

KPV Oral is described as well tolerated per study reports. Since the action lies primarily locally in the gastrointestinal tract, the profile of observable effects remains largely local.

Observed in research and user reports:

  • Gastrointestinal tract: since the compound is used orally with local action at the target tissue, mild gastrointestinal reactions are the most plausible observation.
  • Mild profile: as a short tripeptide, KPV shares the anti-inflammatory action of alpha-MSH without its pigmentary effects and is described as low in side effects in preclinical studies.
  • Immune modulation: KPV reduces NF-kB activation and pro-inflammatory cytokines and modulates the Th17/Treg balance, an active intervention in inflammatory pathways.
  • No long-term data: the data on colitis models is substantial, but it comes predominantly from preclinical models. Robust long-term human data do not exist.

This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

Dosing

Loading dosing information …

More in the lexicon

FAQ

Frequently asked

Sources for every answer: lexicon entry

Still have a question?

Write to us, our team will help you.

DiscordTelegramWhatsApp
Are there studies on KPV as a tablet?

No. There is no published study on the tablet. The gut studies in mice also gave KPV by mouth, though: in drinking water or in carriers that release the compound only in the colon.

Is KPV approved or studied in humans?

No. There is no approval and as of 26 October 2026 ClinicalTrials.gov lists not a single trial with KPV. All data come from cell experiments and animal models.

Why via the gut in particular?

The transporter PepT1 carries small peptides of two or three building blocks into cells, KPV included. PepT1 is barely present in the healthy colon but increased in chronic bowel inflammation. So KPV preferentially reaches the inflamed areas. In mice without PepT1 the effect of KPV on colon tumours after inflammation was absent.

What do the gut models show?

With KPV in the drinking water the inflammation marker MPO fell by about 50 and 30 percent of the rise (two colitis models) and weight loss was smaller. In a model of colon cancer after inflammation fewer tumours formed, but not in a genetic tumour model without inflammation.

What do carriers like nanoparticles add?

They protect KPV on its way through stomach and small intestine and release it in the colon. In nanoparticles a 12,000-fold lower concentration gave a similar effect. A newer conjugate brought 3.8 times more KPV into the colon and worked better even at a 20-fold smaller amount.

Which side effects are known?

There are no solid data because KPV has never been tested in a registered human trial. The nanoparticle carriers did not damage gut cells in cell experiments. That cannot be transferred to humans.